(Q43986512)

28 November 2017

title

Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients (English)

1 reference

28 November 2017

1 reference

R Van Damme-Lombaerts

1

1 reference

28 November 2017

N A Y Webb

2

1 reference

28 November 2017

P F Hoyer

3

1 reference

28 November 2017

J Mahan

4

1 reference

28 November 2017

J Lemire

5

1 reference

28 November 2017

R Ettenger

6

1 reference

28 November 2017

L McMahon

7

1 reference

28 November 2017

N Cambon

8

1 reference

28 November 2017

R Boger

9

1 reference

28 November 2017

J M Kovarik

10

1 reference

28 November 2017

Everolimus Study Group

11

1 reference

28 November 2017

language of work or name

1 reference

1 April 2002

1 reference

Pediatric Transplantation

28 November 2017

published in

1 reference

28 November 2017

volume

6

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

147-152

1 reference

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

Chemical modification of rapamycin: the discovery of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

Steady improvement in renal allograft survival among North American children: a five year appraisal by the North American Pediatric Renal Transplant Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

The potential role of rapamycin in pediatric transplantation as observed from adult studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

Growth after renal transplantation: correlation with immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

Sirolimus: a new agent for prevention of renal allograft rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3046.2002.01070.X

7 January 2021

10.1034/J.1399-3046.2002.01070.X

Identifiers

DOI

1 reference

28 November 2017

1 reference